Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
74 Results for "
model substrate
" in MedChemExpress (MCE) Product Catalog:
Products (74)
74 Results for "model substrate" in MCE Product Catalog:
Cat. No.: HY-161838
ICT10336 is a hypoxia-responsive prodrug of ATR inhibitor, AZD6738 (HY-19323). ICT10336 is hypoxia-activated and specifically releases AZD6738 only in hypoxic conditions in vitro. This can inhibit ATR activation (T1989 and S428 phosphorylation) and subsequently abrogate HIF1a-mediated adaptation of hypoxic cancers cells, thus selectively inducing cell death in 2D and 3D cancer models. ICT10336 is a metabolic substrate of CYPOR activity.
Cat. No.: HY-153321A
CAS No.: 2649400-33-7
Synonyms: (R,R)-NX-5948; (R,R)-BTK-IN-24
Target:
Research Areas:
(R,R)-Bexobrutideg is the (R,R)-enantiomer of Bexobrutideg (HY-153321). Bexobrutideg (NX-5948) is an orally active PROTAC that induces specific BTK protein degradation via a cereblon E3 ligase (CRBN) complex without degrading other cereblon neo substrates. Bexobrutideg mediates potent anti-inflammatory activity through BTK degradation, thereby inhibiting B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models containing wild-type BTK or BTKi resistance mutations. Bexobrutideg is effective in a mouse model of collagen-induced arthritis (CIA). Bexobrutideg can cross the blood-brain barrier. NX-5948 consists of a target protein ligand, a linker, and a VHL E3 ubiquitin ligase (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker) .
Cat. No.: HY-P11297
CAS No.: 194484-75-8
Research Areas:
Cat. No.: HY-162460
CAS No.: 3056077-07-4
ERK1/2 inhibitor 10 (Compound 36c) is a potent ERK1 and ERK2 inhibitor (IC50: 0.11 and 0.08 nM respectively). ERK1/2 inhibitor 10 inhibits ERK1/2 and blocks the phosphorylation expression of their downstream substrates p90RSK and c-Myc. ERK1/2 inhibitor 10 induces cell apoptosis and incomplete autophagy-related cell death. ERK1/2 inhibitor 10 shows potent antitumor efficacy against triple-negative breast cancer and colorectal cancer models harboring BRAF and RAS mutations .
Cat. No.: HY-N3197
CAS No.: 477953-07-4
Synonyms: (+)-Neostenine
Target:
Cat. No.: HY-168143
Target:
Research Areas:
YD1342 is a prodrug of YD1130, which exhibits potent inhibitory effects on cellular substrate methylation, breast cancer cell clonogenicity, and tumor growth in animal models, exceeding or matching known PRMT4-specific inhibitors. .
Cat. No.: HY-149810
CAS No.: 2890177-90-7
AcrB-IN-2 is an AcrB efflux pump inhibitor, with ability to potentiate the effect of antibiotics. AcrB-IN-22 inhibits Nile Red (a known substrate of AcrB) efflux.AcrB-IN-2 does not disrupts the bacterial outer membrane nor display toxicity in a nematode model .
Cat. No.: HY-149811
CAS No.: 2890177-94-1
Efflux pump-IN-3 is an AcrB efflux pump inhibitor, with ability to potentiate the effect of antibiotics. Efflux pump-IN-3 inhibits Nile Red (a known substrate of AcrB) efflux. Efflux pump-IN-3 does not disrupts the bacterial outer membrane nor display toxicity in a nematode model .
Cat. No.: HY-W099580R
CAS No.: 544-76-3
Synonyms: n-Hexadecane (Standard); Cetane (Standard)
Cat. No.: HY-162882
CAS No.: 2482713-67-5
Research Areas:
CC15009 is a xanthine oxidoreductase (XOR) inhibitor, with an IC50 value of 0.237 nM. CC15009 can inhibit the oxidative subtype of XOR, thereby reducing the production of the byproduct ROS and exhibiting antioxidant activity. CC15009 has demonstrated a good dose-dependent uric acid-lowering effect in two different mouse models of hyperuricemia induced by XOR substrates .
Cat. No.: HY-W099580S
CAS No.: 158563-27-0
Synonyms: n-Hexadecane-1,2-13C2; Cetane-1,2-13C2
Cat. No.: HY-W014109
CAS No.: 69304-49-0
Synonyms: (E)-5-(2-Bromovinyl)uracil; BVU
Target:
Research Areas:
(E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time.
Cat. No.: HY-170947
Target:
Research Areas:
Antitumor agent-195 (compound 16c) is a dual targeting agent of STAT3 and NQO1. Antitumor agent-195 significantly inhibits phosphorylation of STAT3 at Tyr705 at a concentration of 1 μM and effectively induce Apoptosis in MDAMB-231 and MDA-MB-468 breast cancer cells. Antitumor agent-195 as a NQO1 substrate strongly increases ROS generation and causes severe DNA damage in a dose-dependent manner. Antitumor agent-195 shows encouraging anti-tumor efficacy in the MDA-MB-231 xenograft model .
Cat. No.: HY-W012597
CAS No.: 1070-34-4
Target:
Target:
Research Areas:
N,S-Diacetylcysteamine is an N-acetylcysteamine thioester (SNAc) derivative that serves as an acetyl donor, substrate, substrate inhibitor, condensing agent, and acyl donor. N,S-Diacetylcysteamine acts as an acetyl donor in the INH (Isoniazid) (HY-B0329) acetylation reaction in rhesus monkey liver homogenate, functions as a substrate for pigeon liver arylamine acetylase, and exhibits substrate inhibition against both systems at excessively high concentrations. N,S-Diacetylcysteamine acts as a substrate for peptidoglycan O-acetyltransferase B (PatB) to mediate the acetylation modification of peptidoglycan, and serves as a thioester model for the thioester groups of acetyl-CoA and acyl carrier protein .
Target:
Research Areas:
4-Methoxybiphenyl is a cytochrome P450-dependent microsomal monooxygenase system substrate and metabolite precursor. 4-Methoxybiphenyl undergoes O-demethylation to generate 4-hydroxybiphenyl. 4-Methoxybiphenyl undergoes sulphation and glucuronidation conjugation; inhibition of sulphation shifts metabolism toward increased glucuronidation and unconjugated 4-hydroxybiphenyl accumulation. 4-Methoxybiphenyl serves as a model substrate for studying phase II metabolic conjugation pathway balance in rat isolated hepatocytes .
Cat. No.: HY-167810
CAS No.: 59891-25-7
Research Areas:
1,3-Dipentadecanoin(C15:0) is a long-chain triglyceride with substrate activity for lipid metabolism studies. 1,3-Dipentadecanoin(C15:0) is used as a model compound for studying the hydrolysis of triglycerides by lipase. 1,3-Dipentadecanoin(C15:0) can help understand the metabolic mechanism of triglycerides in chemical research.
Cat. No.: HY-182567
CAS No.: 2109805-79-8
Nampt-IN-19 is an orally active and non-substrate nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with a human Ki of 5.6 nM. Nampt-IN-19 blocks NAD + biosynthesis from Nicotinamide (HY-B0150). Nampt-IN-19 acts as an antiproliferative agent in cancer cells. Nampt-IN-19 has preclinical pharmacokinetic properties supporting oral antitumor activity in mouse xenograft models. Nampt-IN-19 can be used for the research of colorectal cancer .
Cat. No.: HY-W008719R
CAS No.: 36913-39-0
Research Areas:
MPP+ iodide (Standard) is the analytical standard of MPP+ iodide (HY-W008719). This product is intended for research and analytical applications. MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of ParKinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .
Cat. No.: HY-184706
CAS No.: 3126116-06-8
Research Areas:
SHN7 is a selective HDAC1/HDAC6 inhibitor, NQO1 substrate and ROS inducer, with an IC50 of 30 nM against HDAC1 and an IC50 of 10 nM against HDAC6. SHN7 inhibits STAT3 with a Kd of 8.9 μM. SHN7 arrests the cell cycle at the G2/M phase and induces Apoptosis. SHN7 exhibits anti-tumor effects in triple-negative breast cancer (TNBC) xenograft models. SHN7 can be used for the research of triple-negative breast cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
